MEM-288

MEM-288 is a conditionally-replicative oncolytic adenovirus engineered to express two potent immunomodulatory proteins: human interferon beta (IFNβ) and a recombinant, membrane-stable form of CD40 ligand (CD40L, also referred to as MEM40). Developed by Memgen in collaboration with Moffitt Cancer Center, this viral immunotherapy is designed to selectively infect and lyse cancer cells while simultaneously activating the immune system. The dual transgene approach aims to induce robust dendritic cell-mediated systemic T cell responses against tumors. Preclinical and early clinical studies have shown that MEM-288 can shrink both injected and non-injected tumors, enhance tumor-specific T cell infiltration, remodel the tumor microenvironment, and synergize with immune checkpoint inhibitors such as nivolumab. It is being evaluated primarily for advanced solid tumors including non-small cell lung cancer (NSCLC), but also in other cancers such as pancreatic cancer, triple-negative breast cancer, melanoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, head and neck neoplasms, meningeal neoplasms, brain metastases, and BRAF V600E mutation-positive melanoma[1][2][4][5][6].